Akebia Therapeutics, Inc. (AKBA)
About Akebia Therapeutics, Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $236.2M
- Net income
- -$5.3M
- Total assets
- $376.6M
- Market cap
- $250.9M
- Gross margin
- 83.3%
- Operating margin
- 9.9%
- Net margin
- -2.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $236.2M
- Cost of revenue
- $39.5M
- Gross profit
- $196.7M
- Operating expenses
- $173.2M
- Operating income
- $23.5M
- Income tax
- $1.6M
- Net income
- -$5.3M
- EPS (basic)
- $-0.02
- EPS (diluted)
- $-0.02
Balance sheet
- Total assets
- $376.6M
- Current assets
- $253.0M
- Total liabilities
- $344.0M
- Current liabilities
- $162.9M
- Shareholders’ equity
- $32.6M
Cash flow
- Operating cash flow
- $68.0M
- Investing cash flow
- -$7.9M
- Financing cash flow
- $72.9M
- Net cash flow
- $133.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $250.9M
- EPS (diluted)
- $-0.02
- Shares outstanding
- 205.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 20, 2014
Akebia Therapeutics, Inc. (AKBA) Stock Price
- Reported a net loss of $5.3M in FY2025.
- Revenue grew 11% from FY2021 to FY2025.
- Gross margin of 83.3%, net margin -2.3%.
- Trading 70% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Akebia Therapeutics, Inc..
Write a review
News about Akebia Therapeutics, Inc.
News & sentiment via Polygon.io
Akebia Therapeutics, Inc.: frequently asked questions
Is Akebia Therapeutics, Inc. an American company?
Akebia Therapeutics, Inc. is a US-based company headquartered in Cambridge, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Akebia Therapeutics, Inc. headquartered?
Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, United States.
Is Akebia Therapeutics, Inc. publicly traded?
Yes — Akebia Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol AKBA on the NASDAQ.
What does Akebia Therapeutics, Inc. do?
Akebia Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
